NASDAQ · SYRE
Spyre Therapeutics, Inc.
$95.70-$3.26 (-3.3%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.14% below the high.
Loading market information…
NASDAQ · EYEN · USD
Stock price, earnings
Quote as of Oct 20, 2025, 04:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Eyenovia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Eyenovia, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Eyenovia, Inc., a New York-based company established in 2014 (originally incorporated as PGP Holdings V, Inc.), functions as a clinical-stage pharmaceutical firm specializing in ophthalmology. The company utilizes its exclusive microdose array print platform technology and the Optejet branded targeted ocular delivery system to formulate innovative eye treatments. Its primary focus for research and development lies in addressing progressive myopia (nearsightedness), age-related near vision impairment (presbyopia), and pharmacologically induced pupil dilation for eye examinations. Eyenovia's developmental pipeline includes several advanced candidates, all currently undergoing Phase III clinical trials: MicroLine: Designed to enhance near vision for individuals with presbyopia. MicroPine: Aimed at slowing the progression of nearsightedness in pediatric patients. MydCombi: A microdose fixed-combination treatment intended for pharmaceutical mydriasis. Furthermore, Eyenovia has forged strategic alliances for product commercialization. It maintains a licensing agreement with Bausch Health Ireland Limited for the development and commercialization of MicroPine across the United States and Canada. Additionally, an agreement with Arctic Vision (Hong Kong) Limited covers the development and commercialization of both MicroPine and MicroLine in the markets of China and South Korea.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2023 | Nov 13, 2023 | -$14.40-7,478.95% vs estimate | $1.20M+384.53% vs estimate |
|---|
| Q2 2023 | Aug 10, 2023 | -$12.80-6,300.0% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$95.70-$3.26 (-3.3%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.14% below the high.
$0.30-$0.00 (-0.03%)
GreenLight Biosciences Holdings’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
$0.70-$0.06 (-7.74%)
Magenta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
$1.00-$0.03 (-2.91%)
Pluristem Therapeutics Inc.: Healthcare · Biotechnology.
$2.93-$0.05 (-1.68%)
Cerecor Inc.’s quoted price sits in the lower half of its reported 52-week range, 1.68% below the high.
$4.34$0.00 (0.0%)
Lumos Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.15% below the high.
$1.10$0.00 (0.0%)
Satsuma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.39% below the high.
$0.55$0.00 (0.0%)
Marinus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.76% below the high.
